This page shows the latest serelaxin news and features for those working in and with pharma, biotech and healthcare.
year. A decision to drop development of acute heart failure drug serelaxin (RLX030) also pegged back Novartis' profits, forcing the company to take a charge of $200m in the quarter.
Novartis' acute heart failure therapy misses two main endpoints. The failure of Novartis' acute heart failure therapy serelaxin to hit its objectives in a second phase III trial is somewhat embarrassing ... credibility". Novartis had been hoping to build
The company launched first-in-class chronic heart failure therapy Entresto (sacubitril and valsartan) in 2015 and is hoping to re-file acute heart failure candidate serelaxin (RLX030) this year.
These include RLX030 (serelaxin) for acute heart failure, Fovista (pegpleranib) and RTH258 (brolucizumab) for neovascular age-related macular degeneration (AMD), and novel migraine prevention drug AMG334.
Novartis was less successful in its efforts to secure approval of acute heart failure therapy Reasanz (serelaxin), which was rejected by an FDA advisory committee earlier this year because of a
heart failure drug Reasanz (serelaxin).
More from news
Approximately 8 fully matching, plus 8 partially matching documents found.
Other candidates in mid-stage testing include: natriuretic peptide receptor agonists from Capricor Therapeutics (cenderitide) and Palatin Technologies (PL-3994); Novartis' synthetic human relaxin 2 hormone serelaxin (knocked back by regulators
It's a company with great potential, according to Schnee, who has high hopes for its lead drug candidate ularitide – an investigational product that is in competition with Novartis' serelaxin to ... Because of the serelaxin trial [by Novartis], you saw
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...